Clinical data from Phase 3 trials in Pramlintide

被引：0
|
作者：
不详
机构：
来源：
DIABETES-METABOLISM RESEARCH AND REVIEWS | 1999年 / 15卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：157 / 157
页数：1
相关论文
共 50 条
  • [1] An evaluation of the FDA Responder Endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials
    Macdougall, J. E.
    Johnston, J. M.
    Lavins, B. J.
    Nelson, L. M.
    Williams, V. S. L.
    Carson, R. T.
    Shiff, S. J.
    Shi, K.
    Kurtz, C. B.
    Baird, M. J.
    Currie, M. G.
    Lembo, A. J.
    [J]. NEUROGASTROENTEROLOGY AND MOTILITY, 2013, 25 (06): : 481 - e365
  • [2] Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials
    Bays, Harold E.
    Banach, Maciej
    Catapano, Alberico L.
    Duell, P. Barton
    Gotto, Antonio M., Jr.
    Laufs, Ulrich
    Leiter, Lawrence A.
    Mancini, G. B. John
    Ray, Kausik K.
    Bloedon, LeAnne T.
    Sasiela, William J.
    Ye, Zhan
    Ballantyne, Christie M.
    [J]. JOURNAL OF CLINICAL LIPIDOLOGY, 2020, 14 (05) : 649 - +
  • [3] PREDICTORS OF DEVELOPING LONG COVID FROM PROSPECTIVELY COLLECTED DATA FROM A PHASE 3 CLINICAL TRIALS.
    Belani, Hrishikesh
    Belani, Seema
    Nicklas, Jacinda M.
    Fenno, Sarah
    Erickson, Spencer
    Bramante, Carolyn
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2023, 38 : S125 - S125
  • [4] Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials
    Gallagher, Conor J.
    Bowsher, Ronald R.
    Clancy, Amanda
    Dover, Jeffrey S.
    Humphrey, Shannon
    Liu, Yan
    Prawdzik, Gregg
    [J]. TOXINS, 2023, 15 (01)
  • [5] Impact of source data verification on data quality in clinical trials: an empirical post hoc analysis of three phase 3 randomized clinical trials
    Andersen, Jeppe Ragnar
    Byrjalsen, Inger
    Bihlet, Asger
    Kalakou, Faidra
    Hoeck, Hans Christian
    Hansen, Gitte
    Hansen, Henrik Bo
    Karsdal, Morten Asser
    Riis, Bente Juel
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 79 (04) : 660 - 668
  • [6] Priority safety data issues in late phase clinical trials: A qualitative approach from an academic clinical trials unit
    Wills, Genevieve Helen
    Arenas-Pinto, Alejandro
    Dunn, David
    Goodall, Ruth
    [J]. TRIALS, 2019, 20
  • [7] Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C
    Lacy, B. E.
    Lembo, A. J.
    MacDougall, J. E.
    Shiff, S. J.
    Kurtz, C. B.
    Currie, M. G.
    Johnston, J. M.
    [J]. NEUROGASTROENTEROLOGY AND MOTILITY, 2014, 26 (03): : 326 - 333
  • [8] IXABEPILONE-ASSOCIATED PERIPHERAL NEUROPATHY: RETROSPECTIVE REVIEW OF DATA FROM PHASE 2 AND 3 CLINICAL TRIALS
    Donovan, Diana
    Roche, Henri
    Hortobagyi, Gabriel
    Sparano, Joseph
    Mukhopadhyay, Pralay
    Vahdat, Linda
    [J]. ONCOLOGY NURSING FORUM, 2011, 38 (02) : E121 - E121
  • [9] Liberating the data from clinical trials
    Henry, David
    Fitzpatrick, Tiffany
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2015, 351
  • [10] PROBLEMS IN POOLING DATA FROM 3 INDEPENDENT CLINICAL-TRIALS
    PRUSOFF, BA
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 1979, 110 (03) : 362 - 362
12345